Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition - Imaging Neurodegeneration in Motion: Multimodal Biomarkers for Alzheimer’s Disease and Parkinson’s Disease

Imaging Neurodegeneration in Motion: Multimodal Biomarkers for Alzheimer’s Disease and Parkinson’s Disease

Flash Presentation

Neuro A

Wednesday, 13 May 2026

Roof Terrace

13:40 - 15:16

Moderators: Kay Igwe & Pankaj Pankaj

Session Number: 531-02

No CME/CE Credit

Similar Sessions

This fast-paced power pitch session highlights cutting-edge MRI, PET-informed, and computational approaches to quantify neurodegenerative processes in Alzheimer’s and Parkinson’s disease. Presentations emphasize multimodal biomarkers of protein pathology, vascular and metabolic dysfunction, network disruption, and therapeutic response, with a focus on early detection and disease progression.

13:40		531-02-001. A Multistep-Multitask Approach to Reconstruct Tau PET scans of AD Subjects From Simpler Radiology Inputs Daren Ma, Robin Sandell, Ashish Raj University of California San Francisco, San Francisco, United States of America Impact: We demonstrate that simple clinical, plasma, and MRI data can accurately forecast tau progression traditionally measurable only by tau-PET, marking a major advance toward fully reconstructing voxel-level tau pathology from a single MRI—an ambitious leap toward precision, low-cost neurodegenerative modeling.
13:42		531-02-002. Temporal Dynamics of White Matter and Tau Pathology Across the Alzheimer's Disease: A Cross-Lagged Panel Analysis Using NODDI Takafumi Kitagawa, Kaito Takabayashi, Wataru Uchida, Christina Andica, Koyo Mizuta, Rui Zou, Takuya Ozawa, Akifumi Hagiwara, Shigeki Aoki, Koji Kamagata Juntendo University Graduate School of Medicine, Tokyo, Japan Impact: Cross-lagged analysis reveals stage-dependent reversal: white-matter changes precede tau accumulation in early Alzheimer's disease, potentially reflecting intact clearance mechanisms or structural vulnerability, while established tau pathology drives white-matter degeneration in advanced stages, demonstrating bidirectional temporal dynamics across disease progression.
13:44		531-02-003. Triple-Network Effective Connectivity Predicts Dementia Conversion in Cognitively Normal Adults Zhen Xuen Brandon Low, Lucy Vivash, Terence O'Brien, Adeel Razi, Meng Law, Ben Sinclair Monash University, Melbourne, Australia Impact: These findings demonstrate that modelling directed network interactions provides sensitive and practical biomarkers for early dementia detection, potentially facilitating personalized risk assessment, and targeted preventive interventions.
13:46		531-02-004. Association of OEF, CBF and CMRO2 with Tau Deposition in Older Individuals Hangwei Zhuang, Liangdong Zhou, Xiuyuan Wang, Emily Tanzi, Mony de Leon, Yi Li, Pascal Spincemaille , Ilhami Kovanlikaya, Thanh Nguyen, Yi Wang, Gloria Chiang Cornell University, Ithaca, United States of America Impact: This study links tau pathology with regionally disrupted cerebral oxygen metabolism. OEF and CMRO₂ mapping offer insight into mechanism underlying tau-related neurodegeneration and provide potential novel biomarkers for cognitive decline and pre-clinical AD.
13:48		531-02-005. Associations of Choroid Plexus Perfusion Measured by pCASL MRI with Amyloid Burden and Cognition in elderly adults Zicheng Wang, Tianrui Zhao, Yining He, Sang Hun Chung, Elizabeth Joe, Helena Chui, Lirong Yan Northwestern University, Chicago, United States of America Impact: This work suggests that CBF in ChP can serve as an early biomarker linking cerebrospinal fluid dysfunction to cognitive decline, potentially mediated through an APOE–ChP–CSF regulatory pathway.
13:50		531-02-006. In vivo ³¹P-MRSI of Cerebral Phosphorus Metabolites as Biomarkers for Alzheimer’s Disease shuai zhao, Baiyan Jiang, Meiyun Wang Zhengzhou University People's Hospital & Henan Provincial People's Hospital, Zhengzhou, China Impact: These findings support the potential of ³¹P-MRSI as a noninvasive imaging tool for detecting metabolic alterations associated with Alzheimer's disease, providing important insights for future clinical research and early diagnosis.
13:52		531-02-007. The sub-voxel quantitative susceptibility mapping (QSM) reveals iron and pathological protein alterations in early Alzheimer’ Aocai Yang, Jiaxiang Xin, Tao Gong, guangbin wang Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China Impact: This study establishes sub-voxel QSM as a quantitative imaging biomarker that separately tracks iron and pathological protein alterations in Alzheimer’s disease. The method enables precise monitoring of Lecanemab treatment response and could guide future anti-amyloid and anti-tau therapeutic evaluation.
13:54		531-02-008. Age-related choroid plexus enlargement coupled with changes in cerebral perfusion and functional network segregation Yanli Wu, Lei Gao Zhongnan Hospital of Wuhan University, Wuhan, China Impact: Using ultra-high-field MRI, we show that age-related choroid plexus enlargement is coupled with concurrent reductions in cerebral blood flow and network segregation, indicating coordinated vascular and functional alterations during aging.
13:56		531-02-009. When brains disagree: data ambiguity underlies the challenge of amyloid PET synthesis from structural MRI Louise Baron, Ross Callaghan, David Cash, Philip Weston, Hojjat Azadbakht, Gary Zhang University College London, London, United Kingdom Impact: We show that differences in how MRI and PET capture disease-related signals in Alzheimer’s may explain the limited accuracy of MRI-based amyloid PET synthesis. This previously unrecognised insight can guide the design of more accurate amyloid PET prediction models.
13:58		531-02-010. Thalamic Volume Mediates the Link between Dopaminergic Degeneration and Depression Progression in Parkinson’s Disease Junli Ren Beijing Chaoyang Hospital, Capital Medical University, beijing, China Impact: This study establishes thalamic volume as a clinically viable MRI biomarker for depression progression in Parkinson's disease, revealing how dopaminergic degeneration drives depression via thalamic atrophy and suggesting new therapeutic targets.
14:00		531-02-011. Tract-Specific White Matter Microstructure Predicts Deep Brain Stimulation Response in Parkinson’s Disease Devin Schoen, Philip Shih, Skyler Deutsch, Juhi Mehta, Sarah Wang, John Kornak, Ian Bledsoe, Jill Ostrem, Melanie Morrison University of California San Francisco, San Francisco, United States of America Impact: Preoperative diffusion MRI provides a fast, fully noninvasive biomarker of brain integrity that predicts DBS outcomes, enabling personalized surgical planning and patient selection without requiring computationally intensive tractography or lead localization on postoperative imaging.
14:02		531-02-012. Cerebral Perfusion and Glymphatic Function Alterations in Chronic Thromboembolic Pulmonary Hypertension Shiyu Qi, Tong Yuan, Penghui Sun, Yifei Zhang, Jianfeng Wang, Juanni Gong, Xiuqin Jia, Qi Yang Beijing Chaoyang Hospital, Capital Medical University, beijing, China Impact: This study identifies cerebral hypoperfusion and impaired glymphatic function in CTEPH, with exploratory analysis suggesting greater glymphatic impairment in patients with prior hypertension. These findings highlight the need for cerebrovascular monitoring and motivate future studies on cerebrovascular–glymphatic coupling.
14:04		531-02-013. Patterns of Deep Brain Stimulation Target Engagement Correlate with Postoperative Cognitive Change in Parkinson’s Disease Devin Schoen, Meenakshi Singhal, Skyler Deutsch, Deborah Cahn, Caroline Racine, Sarah Wang, Ian Bledsoe, Jill Ostrem, Philip Starr, Doris Wang, Melanie Morrison University of California San Francisco, San Francisco, United States of America Impact: Identifying how motor, associative, and limbic engagement differentially shape cognitive and mood changes post-DBS can inform surgical targeting and postoperative programming, helping clinicians optimize benefit while minimizing cognitive side effects.
14:06		531-02-014. Investigating Cerebral Blood Flow Changes in Alzheimer's Patients Undergoing Anti-Amyloid Therapy Elena Andree, Conan Chen, Katherine Bangen, Ryan Barnes, Jason Handwerker, Eric Wong, Thomas Liu, Divya Bolar University of Oxford, Oxford, United Kingdom Impact: Our results suggest a correlation between CBF and cognitive changes in Lecanemab therapy, supporting the idea of CBF as an imaging biomarker for clinicians to identify patients most likely to benefit from treatment and elucidate neurovascular contributors to AD pathophysiology.
14:08		531-02-015. Brain Pulsation Imaging: Initial Results at 3T Pål Erik Goa, Abdul Nashirudeen Mumuni, Simon Blömer, Rüdiger Stirnberg, Tony Stoecker Norwegian University of Science and Technology NTNU, Norway Impact: First results at 3T with the recently introduced Brain Pulsation Imaging method reveal high sensitivity and repeatability in quantitative imaging of tissue and fluid pulsatile motion. The method has significant potential for research and clinical applications within brain pulsation.
14:10		531-02-016. Postmortem Insights into CSF Diffusion Across Aging Jose Henrique Monteiro de Azevedo, Khallil Chaim, Maria Garcia Otaduy, Carlos Salmon Inbrain lab, Faculty of Philosophy, Sciences and Letters of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Brazil, Brazil Impact: Our postmortem findings suggest that CSF-to-eye ADC ratio may reflect age-related barrier permeability and protein equilibration, offering new insights into brain aging and neurodegenerative processes. Such effects may be harder to detect in vivo due to CSF flow.
14:12		531-02-017. Age-related Changes in Relaxation Do Not Drive Metabolite Aging Findings Yulu Song, Christopher Davies-Jenkins, Gizeaddis Simegn, Steve Hui, Tao Gong, Saipavitra Murali-Manohar, Vivek Yedavalli , Helge Zoellner, Zahra Shams, Abdelrahman Gad, Dunja Simicic, Aaron Gudmundson, Georg Oeltzschner, guangbin wang, Eric Porges, Richard AE Edden Johns Hopkins University School of Medicine, Baltimore, United States of America Impact: MRS-measured metabolite levels in the brain change significantly over the lifespan. Are age-metabolite correlations driven by concentration levels or confounded by relaxation changes? We investigated the extent to which previous findings were driven by age-dependent errors in relaxation weighting corrections.